I wouldn’t exactly call myself a black belt in beta-blockers, but with all this talk of superiority, "non-superiority," and "non-non-inferiority," it’s really enough to get confused. If I interpret correctly the avalanche of trials from the past year, accompanied by the

Ah, PubMed. “Because of a lapse in government funding, information may not be up to date, transactions may not be processed, and inquiries may not be answered.” In other words: your daily literature search now comes with a side of existential uncertainty.

I have translated into slides the topics and references used by the 2025 Guidelines Task Force on valvular heart disease to justify the recommendation for TAVI in patients aged 70 years or older. Their key argument is a certain degree of pragmatism — they consider age as a

This study indicates that photon-counting detector computed tomography (PCD-CT) provides high diagnostic accuracy for detecting in-stent restenosis in patients with prior coronary stents. This suggests that PCD-CT may be reliably used to evaluate suspected obstructive coronary

We authored this state-of-the-art review, now published in JACC, to provide an updated, comprehensive overview of post–myocardial infarction inflammatory mechanisms and to critically evaluate the emerging clinical evidence on anti-inflammatory therapies for secondary

The PROTECT IV trial is a prospective, multicenter, randomized study evaluating whether routine Impella CP support during high-risk PCI improves outcomes in patients with complex CAD and LVEF ≤40% (n=1,252) deemed unsuitable for surgery. Patients are randomized 1:1 to PCI with

Left atrial appendage occlusion is a valuable option for selected high-risk patients. Recent trials support its safety and effectiveness, but wider adoption will require stronger evidence. The next step in this evolving field is the CLOSURE-AF trial, to be presented at #AHA25.

Leaflet durability remains a major challenge for transcatheter heart valves. Bench studies suggest balloon-expandable TAVI valves often show pinwheeling, linked to reduced durability. The DurAVR system (Anteris Technologies) uses a short-frame, biomimetic leaflet design to

A new research study redefined optimal IVUS minimal stent area (MSA) thresholds for single-stent crossover in unprotected left main disease: proximal left main ≥11.4 mm², distal left main ≥8.4 mm², and left anterior descending ostium ≥8.1 mm². https://t.co/RQz3qdDlJr

In this state-of-the-art review, the authors summarize current antithrombotic strategies for patients undergoing complex PCI and discuss evidence from randomized clinical trials evaluating these regimens in this context. https://t.co/ul5CqPP87Q

The column “Spot the evil typo in the most famous guidelines” is back. After endless rounds of revisions, proofreads, and about 200 pairs of eyes scrutinizing every single word, the evil typo still manages to hide in plain sight, buried among a million words — and once you notice

Here are the Late Breakers from #AHA25. My initial favorites are – coming at you with some New Orleans groove: OPTIMA-AF – Short dual antithrombotic therapy after PCI in patients with atrial fibrillation CLOSURE-AF – Left atrial appendage closure versus medical therapy in AF

I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on

Amazing hotline session at #ESCCongress2025! ⁦@VijayKunadian⁩ ⁦@escardio⁩

Davide Capodanno takes us from trials to practice as he explores the use of #colchicine including his most successful colchicine case & what patients make the best candidates @DFCapodanno #ESCCongress #CVD #atherosclerosis #HeartDisease

Thank you, Prof. Tanboga, super useful as always.

The main message of TAILORED-CHIP is less about confirming a paradigm and more about raising a hypothesis to be tested under proper conditions. Until dedicated trials provide evidence, “tailored” remains a euphemism for “empiric”—a modern label for old-fashioned guesswork.

Managing patients with atrial fibrillation and coronary artery disease remains a challenge. Up to 40% of patients have both conditions and need both anticoagulation and antiplatelet therapy. #ESCCongress

Yet another trial in STEMI with multivessel disease: in OPTION-STEMI, immediate complete revascularization was not shown to be non-inferior to staged complete revascularization during the index admission, looking at death, non-fatal MI, or unplanned revascularization at 1 year.

In patients undergoing #PCI, a personalized #DAPT duration from 3 to 24 months led to a lowered risk of net adverse clinical events than standard care consisting of 12 months of DAPT. https://t.co/N1YFaMUkku #JACC #ESCCongress #WCCardio @piccoloraf @DFCapodanno